Given the strong association of NQO1-related variants with multiple drug treatments (arsenic trioxide, erlotinib, trametinib, and a combination treatment of paclitaxel + epirubicin), we conducted follow-up experiments to better understand the functional role of this gene in anti-cancer drug response. This evidence concerns the gene NQO1 and cancer.